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Arthritis is often associated with intestinal diseases, but the etiology is not known. We developed a rat model
whereby arthritis was reactivated by experimental small bowel bacterial overgrowth (SBBO). Self-limited,
monoarticular arthritis was induced by intra-articular injection of 2 mg of rhamnose peptidoglycan-polysac-
charide derived from group A streptococci into the ankle joints in female Lewis rats. Eleven days after
intra-articular injection, when swelling was resolving, experimental SBBO induced by surgical creation of
jejunal self-filling blind loops reactivated arthritis, but SBBO induced by creation of self-emptying blind loops,
which minimally increases luminal bacteria, and sham operation did not (P < 0.001). Increased joint diam-
eters in rats with self-filling blind loops persisted for at least 56 days after surgery. Reactivation of arthritis
due to SBBO was prevented by anti-tumor necrosis factor alpha antiserum and interleukin 1 receptor
antagonist (P < 0.001), indicating that these cytokines mediate joint swelling secondary to intestinal injury.
Recombinant bactericidal/permeability-increasing protein, an agent which neutralizes endotoxin, and metro-
nidazole, which is active against anaerobic bacteria, prevented arthritis (P < 0.001), but polymyxin B (which
also neutralizes endotoxin) and gentamicin had no effect. Mutanolysin, an enzyme which degrades peptidogly-
can-polysaccharide from group A streptococci, exacerbated arthritis for the first 6 days but then diminished
joint swelling from 12 to 21 days after surgery (P < 0.001). These studies introduce a reproducible animal
model of reactivation of arthritis secondary to intestinal injury and demonstrate a role for bacterial products
from endogenous enteric organisms.
Up to 20% of patients with chronic inflammatory bowel
disease (Crohn’s disease and ulcerative colitis) have recurrent
episodes of migratory, nondeforming, peripheral arthritis
which can be debilitating (25). There is a striking correlation
between the activity and extent of the intestinal disease and the
severity of arthritis. Hepatic, skin, or eye lesions frequently
accompany arthritis as extraintestinal manifestations of inflam-
matory bowel disease. Ten to twenty percent of patients with
jejuno-ileal bypass surgery for morbid obesity develop arthritis
which has been attributed to bacterial overgrowth in the by-
passed loop (31).
Reactive arthritis can occur days to weeks after the onset of
an enteric infection or acquired venereal disease and is gener-
ally self-limited to a period of 2 to 4 months. There is an
association of HLA-B27 positivity in up to 80% of patients with
reactive arthritis (6, 7, 23, 39). Associated enteric pathogens
include Shigella, Salmonella, Yersinia, and Campylobacter spe-
cies, and nonintestinal organisms include Chlamydia trachoma-
tis and Ureaplasma urealyticum. It is thought that bacterial
antigens may cause arthritis, since antigens to C. trachomatis
(16) and Yersinia species (9) have been identified in synovial
fluid. Intravenous injections of Yersinia enterocolitica caused
arthritis in susceptible Lewis rats without infection in the joint
(13). It is also possible that molecular mimicry between bac-
terial proteins and HLA-B27 antigens, for example, in Kleb-
siella infection (39), is involved in the pathogenesis of reactive
arthritis.
Animal models of arthritis, as well as human clinical data,
provide evidence that bacteria and/or bacterial products as well
as genetics play a role in induction and maintenance of arthritis
(4, 13, 15, 25, 26, 32, 38). Lewis rats develop chronic relapsing
arthritis after peptidoglycan-polysaccharide (PG-PS) derived
from group A streptococci (PG-APS) is injected intraperito-
neally, but Fischer and Buffalo rats do not. Chronic arthritis
induced by intra-articular (i.a.) injection (described below) oc-
curs in Lewis rats but not Fischer or Buffalo rats. The HLA-
B27 transgenic rat develops arthritis spontaneously, but when
the rat is placed in a germ-free environment, no arthritis occurs
(37).
Ubiquitous luminal bacteria may be particularly important
in the pathogenesis of reactive arthritis associated with intes-
tinal inflammation (25). A model of self-limited monoarticular
arthritis has been developed by using a single small dose of the
cell wall polymer PG-APS which is injected i.a. in susceptible
Lewis rats. Ankle joint swelling occurs within 24 h of i.a. in-
jection, peaks 2 to 4 days later, and gradually resolves over 10
to 21 days following injection. Spontaneous reactivation of
arthritis is minimal, but systemic injections of low-dose PG-
APS (5), endotoxin (lipopolysaccharide [LPS]) (34) interleukin
1 (IL-1) (27, 33), toxic shock toxin from Staphylococcus aureus
(28), tumor necrosis factor alpha (TNF-a) (35), or platelet-
derived growth factor (35) cause reactivation of arthritis which
develops within 24 h of injection in all rats and is confined to
the PG-APS-injected joint.
In the past, we used experimental small bowel bacterial
overgrowth (SBBO) which follows surgical creation of self-
filling blind loops (SFBLs) to investigate the pathogenesis of
hepatobiliary injury associated with intestinal injury (18–21).
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To further study the link between intestinal injury and reactive
arthritis, we combined the model of experimental SBBO with
the model of monoarticular arthritis caused by i.a. PG-APS
injection. We found that induction of SBBO by creation of
SFBLs, 11 to 21 days after i.a. injection of PG-APS, also re-
activated arthritis. Using cytokine blockers (rabbit anti-murine
TNF-a antiserum [30] and human IL-1 receptor antagonist
[IL-1ra]), antibiotics (metronidazole and gentamicin), agents
which bind LPS (polymyxin B, E-5 [a monoclonal antibody
against the lipid A component of endotoxin], and amino-ter-
minal recombinant bactericidal/permeability-increasing pro-
tein [rBPI23]), and the muralytic enzyme mutanolysin, we in-
vestigated factors that arise from SBBO which could be
involved in reactivating arthritis. We found evidence that
anaerobic bacteria, endogenous PG-PS, and LPS all play a role
in reactivation of arthritis.
(Preliminary data were presented at the American Gastro-
enterology Association meeting held in May 1991 in New Or-
leans, La. [17a].)
MATERIALS AND METHODS
Experimental design. Female Lewis rats (175 to 200 g, obtained from Charles
River and kept in a specific-pathogen-free environment) were injected i.a. into
one ankle joint with PG-APS in a dose equivalent to 2 mg of rhamnose (6 mg [dry
weight]) in 10 ml of phosphate-buffered saline, and 10 ml of buffer was injected
into the contralateral joint as previously described (5, 34). The needle was
inserted through the Achilles tendon above the calcaneous into the vicinity of the
tibiotalar joint. Eleven days after i.a. injection, SFBLs were created so that SBBO
developed. The first experiment compared the effect of SFBLs with the effects of
self-emptying blind loops (SEBLs) and sham operation over a 56-day time
course. After the initial study, SFBLs were created in all rats, with 8 to 12 rats per
group receiving a variety of therapies which were started on the day prior to
SFBL surgery and continued for 21 days, until the rats were killed. At necropsy,
joints were processed for histology and blind loop contents were cultured. Body
weights were measured at the beginning and end of each experiment. Arthritis
was assessed by blinded daily measurement of lateral ankle joint diameters, using
a Fowler Ultra-Cal II digital caliper (Lux Scientific Instrument Corp., New York,
N.Y.). The data are presented as the change in joint diameter (in millimeters)
from the measurement taken prior to blind loop surgery. With each set of
experiments, control groups consisted of rats with SFBLs treated with a nonac-
tive agent as well as rats with SFBLs receiving no treatment, which served a
positive control.
Treatments included the following: (i) metronidazole (40 mg/kg/day; Schein
Pharmaceuticals, Port Washington, N.Y.) in drinking water; (ii) gentamicin (30
mg/kg/day; Gensia Pharmaceuticals, San Diego, Calif.) in drinking water; (iii)
polymyxin B (5,000 U/day; Sigma Chemical Co., St. Louis, Mo.) by daily subcu-
taneous injection; (iv) rBPI23 (1 mg/kg) every 2 days intravenously (i.v.) or the
control nonactive protein thaumatin (1 mg/kg) (both generous gifts of XOMA
Corp., Berkeley, Calif.; rBPI23 [lot no. BH212003] was produced and purified as
described previously [8] and supplied at a final protein concentration of 1.3
mg/ml in 20 mM sodium citrate and 0.15 mM NaCl [pH 5.0]; thaumatin [lot no.
1134-921221] was supplied as a 1-mg/ml solution in the same buffer as rBPI23 and
has the same pI as rBPI23); (v) 1 E-5 antibody or the nonactive control B-55
antibody (1 mg/kg/day; XOMA Corp.) by i.v. injection (the E-5 antibody is a
murine monoclonal immunoglobulin M antibody specific for the lipid A moiety
of LPS which is produced from mouse ascites; the immunogen was J5 [Rc]
mutant Escherichia coli O111 [12], and the antibody was supplied at a concen-
tration of 2 mg/ml in 5 mmol of sodium phosphate per liter–0.9% NaCl with
0.1% polysorbate 80 at pH 7.3; B-55 is a murine isotype control antibody pro-
vided in a concentration of 2.25 mg/ml in 5 mmol of sodium phosphate per
liter–150 mmol of NaCl per liter–0.1% polysorbate 80 at pH 7.3); (vi) rabbit
anti-mouse TNF-a antiserum or preimmune rabbit serum (1 ml every 2 days; L.
Moldawer, Cornell University, New York, N.Y.) by intraperitoneal injection;
(vii) human IL-1ra (8 mg/kg/day; Synergen, Boulder, Colo.) by subcutaneous
injection divided into four daily doses (the control material was an equivalent
weight of human serum albumin [HSA]); (viii) mutanolysin (10 to 100 mg/day;
Sigma) by i.v. injection or, as control, i.v. phosphate buffer (pH 6.1). For drugs
administered in drinking water as described previously (18–20), the dose was
calculated on the basis of water intake of 20 ml per day, and absolute intake was
monitored daily to ensure this minimal fluid intake. At the doses used, no rats
refused to drink a minimum of 20 ml daily.
In some experiments, 400 mg of LPS (E. coli O55:B5; Sigma) or 400 mg of
PG-APS was administered i.v. to reactivate arthritis.
Preparation of PG-APS. The culturing and harvesting of group A streptococci,
isolation of cell walls, sonication, and separation of PG-APS polymers have been
described in detail elsewhere (36). The fraction injected (100 3 g pellet) ranged
from 50 3 106 to 500 3 106 Da and was documented to be sterile. The amount
of PG-APS in each preparation was determined by measurement of rhamnose,
which constitutes approximately one-third of the dry weight of PG-APS. Values
of PG-APS in this study are expressed in rhamnose weight.
Creation of bacterial overgrowth by using jejunal SFBLs. Ten-centimeter
jejunal SFBLs were created 7 cm distal to the ligament of Treitz, using sterile
technique and ether anesthesia as described by Cameron et al. (3). Control
groups consisted of sham-operated rats that had a laparotomy but no intestinal
anastomosis and did not develop SBBO. Another control group consisted of rats
with SEBLs in which a similar-size loop is constructed in an isoperistaltic fashion
to empty continuously. Although SEBLs have a slight increase in bacteria, man-
ifestations of SBBO do not develop (21, 29).
Bacterial cultures. Blind loops were removed and flushed with 10 ml of iced
saline. Fluid was collected, homogenized, serially diluted 1021 to 10210 in brain
heart infusion medium, and cultured anaerobically (21) in BBL GasPak jars
(Becton Dickinson, Cockeysville, Md.). Bacteroides sp. was selected on bile-based
esculin agar plates (Gibson Laboratory, Lexington, Ky.).
Histology. When rats were killed, ankle joints were removed, placed in 10%
buffered formalin, processed for histological examination, and stained with he-
matoxylin and eosin. A histology score was established by our pathologist, who
assessed synovitis, bone destruction, cartilage destruction, and new bone forma-
tion on a scale of 0 to 3, with the most severe being given a score of 3. Therefore,
the maximum score (most abnormal histologically) was 12.
Statistics. Weights, bacterial counts, and histology score were compared by
using the two-tailed Student’s t test. Values are expressed as means 6 standard
deviations (SD) unless otherwise stated. Differences were considered statistically
significant when P was ,0.05. Changes in joint diameters were compared by
using overall repeated-measures analysis of variance (ANOVA) and pairwise
analysis with ANOVA using the Statview SE program with a Macintosh com-
puter. Significance was considered P , 0.05 for the analysis using ANOVA.
RESULTS
Weight gain and blind loop contents. Control treatment
consisted of a group of rats with SEBLs, groups of rats with
SFBLs which received no treatment, and those which received
the nonactive agents B-55 (control for E-5), thaumatin (control
for rBPI23); i.v. phosphate buffer (control for mutanolysin),
preimmune rabbit serum (control for anti-TNF-a antibody),
and HSA (control for human IL-1ra). During 21 days, sham-
operated rats and those with SEBLs gained approximately 25
6 8 g. With no treatment or appropriate nonactive agents,
Lewis rats with SFBLs gained only 5 6 10 g during the 21 days
after surgery (Table 1). SFBL surgery caused initial weight
loss, and SBBO causes continued poor caloric intake. How-
ever, rats with SFBLs which were treated with metronidazole,
TABLE 1. Weight gain and blind loop bacterial counts in rats with
and without treatmenta








Control-sham 26 6 5* 3.6 6 0.8 0**
Control-SEBL 28 6 7* 5.1 6 1.3 2.3 6 1.2**
Control-SFBL 5 6 10 8.9 6 1.3 8.3 6 123
Anti-TNF 18 6 8* 9.4 6 1.9 8.3 6 0.8
IL-1ra 13 6 7 8.6 6 1.3 7.6 6 1.5
Metronidazole 26 6 9** 7.4 6 0.8 0**
rBPI23 13 6 8 8.4 6 1.4 8.1 6 1.7
Polymyxin B 9 6 10 9.1 6 1.1 8.9 6 1.5
E-5 5 6 6 9.3 6 1.6 8.8 6 0.7
Gentamicin 4 6 3 8.4 6 1.4 7.9 6 1.6
Mutanolysin 19 6 7* 8.6 6 0.9 7.8 6 1.2
a Level of significance of difference compared with SFBL controls; *, P, 0.05;
**, P , 0.005.
b Control-sham, a group of rats with sham operation which received no treat-
ment. Control-SEBL, a group of rats with SEBLs which received no treatment.
Control-SFBL, a group of rats with SFBLs which received no treatment. This
group had weight gain, and bacterial counts which were not significantly different
from those in groups with SFBL treated with nonactive agents such as phosphate
buffer, thaumatin, B-55, and HSA.
c During 21 days after SFBL surgery (6 to 10 rats per group).
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mutanolysin, or anti-TNF-a antiserum gained weight signifi-
cantly better (P, 0.05) than rats with SFBL and no treatment.
Rats treated with human IL-1ra or rBPI23 had slightly greater,
but not statistically significant, weight gain compared with non-
treated rats with SFBLs. Total anaerobic blind loop bacterial
counts were not significantly different among groups. Bacte-
roides sp. counts were significantly different in rats with sham
operation and SEBLs and in rats with SFBLs treated with
metronidazole.
The overall perioperative mortality rate (i.e., from days 0 to
10) following SFBL surgery was 15%, and a further 7% of rats
with SFBLs died between day 11 and 21. The perioperative
mortality rate for rats with SEBLs was 12.5%, with no later
deaths.
Reactivation of arthritis occurs in rats with SFBLs but not
with SEBLs or in sham-operated rats. Following i.a. injection,
joint diameters increased from a baseline average of 6.7 mm to
peak value of 8.2 mm 3 to 5 days after injection and gradually
subsided to an average of 7.2 mm by 11 days after injection. In
Fig. 1 to 4, many groups show negative values for change in
joint diameter. This occurs because joint diameters on the day
of SFBL surgery are approximately 7.2 mm, and they are still
able to decrease to approximately 6.7 mm following appropri-
ate treatment.
Eleven days after i.a. injection, SFBL surgery was per-
formed. Reactivation of arthritis occurred in all rats in this
group and peaked 5 to 10 days after surgery (Fig. 1). Rats with
SFBLs develop SBBO within 1 to 2 days due to stagnation of
blind loop contents (3, 29). Reactivation of arthritis is defined
as an increase in joint diameter by $0.3 mm. Rats with sham
operation showed no reactivation of arthritis. Two of seven
rats with SEBLs developed reactivation of arthritis, although
the mean magnitude of joint swelling in this control group was
significantly less than rats with SFBLs at all time points (P ,
0.001). There were no significant changes in ankle diameters
injected with saline in any group (data not shown).
Since most of our previous studies inducing reactivation with
LPS (27, 33), PG-APS (5), or toxic shock syndrome toxin (28)
had been done 21 days after i.a. injection, we studied reacti-
vation of arthritis induced by SBBO 21 days after i.a. injection
in one group and compared this with reactivation induced by
SBBO 11 days after i.a. injection. In a group of 10 rats with
SFBLs created 21 days after i.a. injection, reactivation of ar-
thritis occurred which was not significantly different than when
SFBLs were created 11 days after i.a. injection (Fig. 1).
Effect of cytokine blockade. Both rabbit anti-TNF-a anti-
serum and human IL-1ra prevented reactivation caused by
SBBO at a level of significance of P , 0.001 compared with
HSA-treated rats, with rats which received no treatment (Fig.
2), and with rats treated with preimmune rabbit serum. No rats
in either the anti-TNF-a antiserum- or IL-1ra-treated group
demonstrated reactivation of arthritis. The first change in joint
diameter which was statistically lower than that of controls
occurred by day 3 for IL-1ra and day 6 for anti-TNF-a anti-
body.
Treatments aimed at blocking the effect of LPS. Rats which
received no treatment and rats treated with nonactive agents
(thaumatin for rBPI23 and B-55 for E-5) failed to prevent
reactivation of arthritis induced by SBBO. The murine anti-
lipid A antibody E-5 and polymyxin B also failed to prevent
reactivation of injury. However, rBPI23 caused a statistically
significant inhibition of reactivation of arthritis (P , 0.001)
which was apparent 5 days after SFBL surgery (Fig. 3).
Effect of antibiotics and the muralytic enzyme mutanolysin
on reactivation of arthritis. Metronidazole prevented reacti-
vation of arthritis induced by SBBO (P , 0.001), with signifi-
cant reduction in joint diameter beginning day 4, but gentami-
cin had no effect (Fig. 4). It should be noted that rats treated
with metronidazole had fewer anaerobic bacteria in the blind
loops and virtually no Bacteroides sp. (Table 1).
Mutanolysin, which was administered i.v. beginning 1 day
before SFBL surgery, consistently caused a bimodal pattern of
response to reactivation of arthritis. Joint swelling increased
acutely after starting mutanolysin and persisted for approxi-
mately 5 days. Once the exacerbation of arthritis subsided,
joint diameters declined steadily, and there was significantly
less joint swelling than control groups from days 12 to 21 (P ,
0.001) (Fig. 4). However, at these time points, metronidazole
treatment demonstrated even less joint swelling than was
found in mutanolysin-treated rats. By repeated-measures
FIG. 1. Change in joint diameter in PG-APS-injected ankle joint following
surgery. All rats were injected i.a. with PG-APS in one ankle and saline in the
contralateral ankle. SFBL (21) is a group of 10 rats which received PG-APS i.a.,
with SFBL surgery performed 21 days later. Surgery was performed 11 days after
i.a. injection in all other groups (sham, n 5 9; SEBL, n 5 7; SFBL, n 5 10). By
repeated-measures ANOVA, the change in joint diameter of the group of rats
with SFBLs was significantly different than in the groups of rats with SEBLs or
sham operation (P , 0.001). No significant changes occurred in the ankles
injected with saline (data not shown).
FIG. 2. Change in joint diameter following SFBL surgery with and without
cytokine blockade. In all groups, PG-APS was injected i.a. and SFBL surgery was
performed 11 days later. For rats with no treatment (Rx), n5 8; for rats receiving
HSA treatment, n 5 10; for rats treated with preimmune serum, n 5 10; for rats
treated with anti-TNF-a antiserum, n 5 8; for rats treated with IL-1ra, n 5 10.
Compared with the HSA-treated and no-treatment groups, joint diameters were
significantly less in rats treated with anti-TNF-a antiserum (P , 0.001) and were
significantly less in rats treated with IL-1ra (P, 0.001), using repeated-measures
ANOVA. The first time point at which joint diameters were significantly lower
than in the three control groups was day 5.
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ANOVA, metronidazole-treated rats had significantly less
joint swelling than mutanolysin-treated rats over the entire 21
days of joint measurements (P, 0.001). In an attempt to blunt
the initial exacerbation of arthritis caused by mutanolysin, this
study was repeated with mutanolysin at 10, 20, 50, and 100 mg
per dose, but the early exacerbation of arthritis occurred each
time. Figure 4 shows the results with mutanolysin at 20 mg per
dose.
Previous studies showed that administration of a single
400-mg dose of mutanolysin 7 days after i.a. injection of PG-
APS prevented reactivation of arthritis by i.v. injection of LPS
2 weeks later (34). Therefore, in order to interpret the effect of
mutanolysin in the experiments described above and in Fig. 4,
it was important to determine whether mutanolysin diminished
the potential of the joint to reactivate by degrading the initial
PG-APS injected i.a. If the joint could not be reactivated by
LPS or PG-APS following this daily schedule of mutanolysin
treatment, then no assessment of its ability to prevent SBBO-
induced reactivation, by degrading SBBO-derived PG-PS,
could be made. To test the effect of mutanolysin treatment on
the ability of the joint to reactivate, the following study was
performed. Thirty rats received PG-APS i.a., and SFBLs were
created 11 days later in 20 rats. A group of 10 rats had no SFBL
surgery. Ten rats with SFBLs were treated daily with 20 mg of
mutanolysin daily i.v. from 1 day prior to SFBL surgery until 19
days after surgery, and the other 10 rats with SFBLs were
treated with phosphate buffer. On day 21, 400 mg of LPS or 400
mg of PG-APS was administered i.v. to five rats per group, and
joints were measured 4, 8, 12, 24, and 48 h after i.v. injection.
In all rats, reactivation of arthritis occurred within 24 h (Table
2). The 10 rats without SFBLs were injected with the same
doses of LPS (n 5 5) or PG-APS (n 5 5). These rats demon-
strated reactivation of arthritis with the same increased mag-
nitude of joint diameter as the other groups. Therefore, the
presence of SBBO and/or daily mutanolysin treatment did not
prevent or potentiate acute reactivation of arthritis by i.v. LPS
or PG-APS. Since the joint was not rendered resistant to re-
activation by this mutanolysin treatment schedule, and reacti-
vation was diminished by mutanolysin 12 to 21 days after sur-
gery (Fig. 4), we conclude that endogenous PG-PS from SBBO
contributes to the pathogenesis of reactivation of arthritis.
Histology of joints. Because the peak of reactivation of the
PG-APS-injected joints occurred approximately 7 days after
SFBL surgery, joints were examined in one experiment at this
time point. With a blinded grading system assessing synovitis,
bone erosion, new bone formation, and tendonitis, rats with
SFBLs had significantly more severe joint pathology (score 5
4.3 6 1.4, mean 6 SD) compared with those with SEBLs
(score 5 2.2 6 0.7, mean 6 SD) and sham operation (score 5
2.0 6 0.6, mean 6 SD) at a level of significance of P , 0.05.
The residual histologic changes from the initial i.a. injection
accounted for the scores of 2.0 to 2.2 in controls when joints
were examined 7 days after surgery. An example of a severely
affected joint is shown in Fig. 5. There is marked synovitis with
pannus formation. Some bony erosion is demonstrated as well.
Saline-injected joints showed no histologic abnormalities (data
not shown).
FIG. 3. Change in joint diameter following SFBL surgery with anti-LPS ther-
apy. All rats were given PG-APS i.a. and SFBL surgery was performed 11 days
later. For rats with thaumatin (Thaum), n 5 9; for rats treated with polymyxin B
(Poly B), n 5 7; for rats treated with E-5, n 5 11; for rats treated with rBPI23,
n 5 7. Compared with the thaumatin-treated, polymyxin B-treated, and E-5-
treated groups, joint diameters were significantly less in rats treated with rBPI23
(P , 0.001), using repeated-measures ANOVA. Joint diameters were signifi-
cantly lower than in controls on days 5, 6, 7, and 9 to 21.
FIG. 4. Change in joint diameter following SFBL surgery with antibiotic and
muralytic therapy. All rats were given PG-APS i.a., and SFBL surgery was
performed 11 days later. For rats receiving metronidazole (Metro), n 5 12; for
rats treated with i.v. mutanolysin (Mutano), n 5 8; for rats treated with i.v.
buffered phosphate (Buff), n 5 7; for rats with gentamicin (Gent), n 5 6.
Compared with rats treated with i.v. buffer and gentamicin, joint diameters were
significantly less in rats treated with metronidazole (P , 0.001), using repeated-
measures ANOVA. Mutanolysin-treated rats demonstrated significantly smaller
swollen joint diameters compared with i.v. buffer- and gentamicin-treated groups
from days 12 to 21 (P , 0.001), using repeated-measures ANOVA. Metronida-
zole-treated rats had significantly less change in joint diameters from days 4 to 21
compared with mutanolysin treatment.
TABLE 2. Reactivation of arthritis after i.v. injections of LPS
or PG-APS
Groupa
Mean change in joint diameter (mm) 6
SD
LPS i.v. PG-APS i.v.
No SFBL-mutanolysin 0.47 6 0.11 0.50 6 0.10
SFBL-mutanolysin 0.55 6 0.22 0.56 6 0.18
SFBL-buffer 0.596 0.32 0.52 6 0.21
a The no SFBL-mutanolysin group was injected with PG-APS i.a. Treatment
with i.v. mutanolysin (20 mg/day) began 1 day prior to i.a. injection and continued
for 19 days after. Twenty-one days after i.a. injection, LPS or PG-APS was given
i.v., and joint diameters were measured. Values are the peak increases in joint
diameter which occurred at 8 to 12 h after i.v. injection. Each group had five rats.
The SFBL-mutanolysin group was injected with PG-APS i.a., and an SFBL was
created 11 days later. Mutanolysin treatment began 1 day prior to SFBL surgery
and was continued for 19 days after. LPS or PG-APS was administered, and
joints were measured as described above. The SFBL-buffer group was handled
similarly except that phosphate buffer (pH 6.1) was administered instead of
mutanolysin. No differences were found among the three groups.
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DISCUSSION
These studies demonstrate that once a joint is injured by i.a.
injection of PG-APS, swelling can be reactivated by the cre-
ation of jejunal SBBO. Previous joint injury is an essential
element in this model, since the contralateral ankle injected
with saline did not demonstrate clinical or histological evi-
dence of inflammation. Creation of SEBLs, which induce only
small increases in luminal bacteria but involve the same surgi-
cal trauma, or sham operation did not cause significant reac-
tivation of arthritis. Therefore, the stress of surgery itself was
not responsible for joint injury, suggesting a primary role for
luminal bacterial overgrowth. The most effective agents which
prevented reactivation of arthritis after the creation of SBBO
were recombinant human IL-1ra, rabbit anti-TNF-a anti-
serum, metronidazole, and rBPI23. Mutanolysin had an inter-
mediate effect. Other treatments designed to prevent the ef-
fects of LPS, including gentamicin, polymyxin B, and E-5, an
antiendotoxin antibody, failed to block recurrent arthritis in-
duced by SBBO.
Metronidazole prevented reactivation of arthritis following
creation of SFBLs, implicating anaerobic bacteria in this
model. Metronidazole has been used in many studies of rat
SBBO because it is able to reverse disaccharidase deficiency,
steatorrhea, protein-losing enteropathy (29), and hepatobiliary
injury induced by SBBO (18). Metronidazole prevents absorp-
tion of PG-APS from blind loops into the systemic circulation,
presumably by preventing intestinal mucosal injury (19). The
blind loops are still distended, occupy the same volume as in
nontreated animals, and actually have only 1 log fewer total
bacterial organisms than rats with other treatments, but they
contain virtually no Bacteroides sp. Therefore, our data suggest
that Bacteroides sp. are important in the pathogenesis of reac-
tivation of arthritis in this model, but the precise mechanism is
not yet determined. Possible mechanisms include suppression
of (i) mucosal permeability, thereby diminishing absorption of
proinflammatory agents from the blind loop; (ii) cytokine re-
lease or stimulation of T cells; and/or (iii) a specific product
from Bacteroides sp., possibly a superantigen analogous to toxic
shock syndrome toxin (28). It is noteworthy that metronidazole
effectively treats arthritis in patients with jejunoileal bypass
surgery for morbid obesity (31). Other data show that metro-
nidazole may function as an immunosuppressant (11) or as an
agent which prevents adhesion of circulating effector cells to
endothelial cells (1). Gentamicin did not prevent reactivation
of arthritis, as expected, since it had no beneficial effect on
SBBO-induced disaccharidase deficiency, steatorrhea (29), or
hepatobiliary disease (18). This finding suggests that aerobic
flora are less important in the pathogenesis of reactivation of
arthritis than anaerobic flora in this model.
That either anti-TNF-a antiserum or IL-1ra prevented re-
activation of arthritis indicates that TNF-a and IL-1 are in-
volved in a common pathway which induces joint inflammation
in this model. This observation is consistent with previous
studies which showed that IL-ra and anti-TNF-a antiserum
prevented reactivation of arthritis induced by i.a. PG-APS fol-
lowing i.v. injection of LPS (27, 28). Staton et al. showed that
IL-1 mRNA was increased in joints injected i.a. with PG-APS
(30a). Furthermore, IL-1 or TNF-a administered i.a. can re-
FIG. 5. Photomicrograph of a rat ankle joint. This female Lewis rat was injected i.a. with PG-APS 11 days prior to SFBL surgery. The rat was killed 7 days after
SFBL surgery, when joint diameters demonstrated maximum swelling, and placed in formalin. Magnification, 3100; stained with hematoxylin and eosin. There is
synovitis and pannus formation as well as bony erosion.
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activate PG-APS-induced arthritis (30a, 33). However, these
results do not show the mechanism by which jejunal bacterial
overgrowth activates cytokine production. We hypothesize that
reactivation of arthritis in this model could occur as a result of
several mechanisms. (i) There may be systemic absorption of
bacterial polymers, such as LPS and/or PG-PS, from the intes-
tinal lumen and deposition directly in the injured joint or in the
liver which incites proinflammatory cytokine production by
resident immune cells (19, 22, 25). (ii) The inflamed intestine
may release cytokines into the systemic circulation. (iii) Arthri-
togenic T-cell populations may be induced from the intestinal
mucosa, mesenteric lymph nodes, or the joint itself. None of
these potential mechanisms have been addressed in these stud-
ies, but each of these possibilities is suggested by previous
studies which demonstrate that i.v. injection of PG-APS (5) or
LPS (34) and i.a. injection of IL-1 (33) can reactivate arthritis.
Furthermore, PG-PS is absorbed from the injured intestine in
the presence of SBBO (19), and plasma levels of TNF-a are
elevated (20). As well, PG-PS derived from normal anaerobic
bacteria (5) and Eubacterium contorti (6) is able to induce
arthritis in rats, and PG-PS is capable of inducing IL-1 and
TNF-a from macrophages (22, 22a). T lymphocytes have been
implicated in reactivation of arthritis by studies using nude rats
(34), superantigen, and cyclosporin (28).
The role of LPS in causing reactivation of arthritis by SBBO
is unclear at this point. Evidence against the importance of
LPS in this model is that E-5, an anti-lipid A antibody (2), and
polymyxin B failed to prevent reactivation of arthritis. E-5
binds LPS and enhances its clearance from the bloodstream by
increasing the rate of uptake into the reticuloendothelial sys-
tem (10). Polymyxin B also binds LPS, and its ineffectiveness in
this study could be dose related. We used 5,000 U per rat
(6,500 U is approximately 1 mg) given as a single subcutaneous
injection, which is in the range for parenteral doses recom-
mended for humans. However, higher doses were neurotoxic
when used in preliminary studies and previously in other stud-
ies (20). Gentamicin, which decreases E. coli counts but does
not totally eliminate them from the blind loop, also failed to
prevent reactivation of arthritis. Schwab et al. showed that
anti-TNF-a antiserum failed to prevent reactivation of arthritis
caused by i.v. LPS (28) but did prevent reactivation of arthritis
by PG-APS.
In favor of an important role for LPS in SBBO-induced
reactivation of arthritis is the fact that rBPI23 prevented reac-
tivation of arthritis. BPI is an antibacterial protein that is
stored in granules of polymorphonuclear leukocytes and is
released into phagocytic vacuoles (24). rBPI23 is considered a
weak bactericidal agent, with most activity against gram-nega-
tive organisms. In one study, it inhibited in vitro bacterial
growth by 92% (17), but in the present study, it had no effect
on total SFBL luminal bacterial concentrations. rBPI23 binds
endotoxin and prevents cytokine release in macrophage cell
cultures. rBPI23 may be effective in this model because of its
ability to neutralize LPS, its bactericidal effect on a subpopu-
lation of enteric organisms, or perhaps a property not yet
determined.
Mutanolysin, a muralytic enzyme whose only known func-
tion is to degrade PG-PS (14), had a biphasic effect on joint
inflammation induced by SBBO. For the first 6 days after the
beginning of mutanolysin therapy, joint diameters increased
significantly, but this was followed by a sharp decline in joint
diameter. This initial increase in joint swelling is consistent
with earlier reports (14). We postulate that this increase in
joint inflammation is due to partial degradation of PG-APS
retained within the joint which liberates more proinflammatory
PG fragments or unmasks more antigenic sites. From 12 to 21
days after creation of SFBLs, mutanolysin demonstrated an
anti-inflammatory effect, presumably reflecting degradation of
endogenous PG-PS derived from the blind loop to biologically
inactive structures (14). Mutanolysin has been shown to pre-
vent arthritis following intraperitoneal injection of PG-APS
(14), and it prevented hepatobiliary injury due to SBBO (20).
Following i.a. injection of PG-APS in rats with or without blind
loops and 19 subsequent days of mutanolysin treatment, reac-
tivation of arthritis still occurred in rats given i.v. LPS or
PG-APS (Table 2). Therefore, mutanolysin did not render the
joint resistant to reactivation of arthritis. Stimpson et al.
showed that a single large dose (400 mg) of mutanolysin 7 days
after i.a. injection of PG-APS did prevent reactivation of ar-
thritis induced by IV LPS on day 19 (34), but only 25 mg of
Salmonella typhimurium Re mutant strain G30/C21 endotoxin
was used, whereas 400 mg of E. coliO55:B5 endotoxin was used
in our experiments. As well, we used a daily dose of 20 mg of
mutanolysin, whereas Stimpson et al. used a single larger dose.
For each therapy tested, simultaneous control groups with
SFBLs which received nonactive agents or no treatment were
also studied. The control groups demonstrated some variability
in the chronicity of inflammation from one experiment to an-
other, although peak arthritis consistently occurred between 3
and 10 days after SFBL surgery. Sometimes controls showed a
gradual decline in ankle joint diameters after the initial reac-
tivation of arthritis (Fig. 1 to 3), while in other experiments,
joint diameters remained elevated (Fig. 4). There is some
variability among rats with respect to their initial response to
PG-APS even though a single source of PG-APS and inbred
rats was used for all studies. There could be subtle differences
in intestinal bacterial colonization, since although rats were all
purchased from the same source and housed in the same spe-
cific-pathogen-free facility, experiments were performed over
several years. Exact duplication of SFBL surgery is difficult, but
in our experience, loops were remarkably similar, when eval-
uated by loop and stool weights.
This reproducible model of SBBO-induced reactivation of
arthritis links intestinal disease to arthritis and provides further
support for the hypothesis that products derived from normal
microbial flora contribute to the etiology of inflammatory ar-
thritis (25, 26, 32). It is not an exact copy of reactive arthritis
secondary to an intestinal infection or a copy of arthritis asso-
ciated with inflammatory bowel disease but most closely re-
sembles arthritis associated with jejunoileal bypass (31). How-
ever, this model will be useful in studying mechanisms of
arthritis related to inflammatory bowel disease and reactive
arthritis from intestinal infections such as those caused Yer-
sinia, Salmonella, and Campylobacter species and other organ-
isms (25). The model could also be used to answer several
important questions such as the role of T cells in reactivation
of arthritis and perhaps determine their origin (e.g., the in-
flamed intestine). SBBO induces increased joint swelling which
gradually subsides despite the continued presence of SBBO.
Therefore, this model could provide insight into how the im-
mune system down-regulates the proinflammatory effect to
endogenous bacterial products. This understanding may give
rise to new treatment strategies and new insights into reactive
arthritis associated with infections and chronic inflammatory
bowel disease.
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